Recombinant protein and fragments thereof, method for producing said recombinant protein, synthetic gene and use of the recombinant protein

A technology of recombinant protein and synthetic gene, which is applied in the fields of pharmacy, molecular biology, medicinal chemistry, biochemistry and genetics, and can solve problems such as short half-life

Pending Publication Date: 2020-03-31
FUNDACAO BUTANTAN
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Of all the leech peptides, bivalirudin, an FDA-approved anticoa

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant protein and fragments thereof, method for producing said recombinant protein, synthetic gene and use of the recombinant protein
  • Recombinant protein and fragments thereof, method for producing said recombinant protein, synthetic gene and use of the recombinant protein
  • Recombinant protein and fragments thereof, method for producing said recombinant protein, synthetic gene and use of the recombinant protein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0073] Here, a novel class of thrombin inhibitors, in particular direct and specific thrombin inhibitors modified from sculptin identified in transcriptome analysis of tick salivary glands, will be described. It consists of 168 residues with four identical repeats and exhibits evolutionary divergence from classical hirudins. The recombinant protein is a competitive, specific and reversible thrombin inhibitor with a K of 18.5±2.2pM. It is slowly digested by thrombin and loses its inhibitory activity. Thus, the recombinant protein is hydrolyzed by Factor Xa, and each polypeptide fragment is capable of inhibiting thrombin in an independent manner. A single domain of the recombinant protein, which retains only about 45% of its inhibitory activity, has been proposed to bind thrombin in a bivalent fashion. Forming a helix / small turn-like structure by incorporating residues from the active site of the recombinant protein domain would make it the most potent thrombin inhibitor compar

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention falls within the fields of biochemistry, molecular biology, genetics, pharmacy and medicinal chemistry, being related to biochemical and metabolic processes. More specifically, the present invention provides a novel class of proteins that inhibit thrombin, particularly direct inhibitors of thrombin modified from sculptin, identified in the transcriptomics analysis of the salivary glands of ticks, as well as fragments and recombinant protein thereof, which can be used as anticoagulant agents and for the prophylaxis and/or treatment of thromboembolic diseases.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner FUNDACAO BUTANTAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products